Dr Miri Halperin Wernli
Group CEO, Co – Founder and Executive Director
Dr. Halperin Wernli is a senior pharmaceutical and biomedical executive with over 25 years of strategic and operational leadership in the biopharmaceutical industry and a deep understanding of drug and product development.
Dr. Halperin Wernli has held worldwide senior leadership positions in product development, R&D and Strategic Marketing throughout Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals).
Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas.
Dr. Halperin Wernli is an experienced Pharmaceutical leader with skills and broad expertise in Drug Development, Regulatory Affairs, Project & Portfolio Management, Development Finance & Controlling, and Corporate Strategy and Governance.
Miri's depth of experience in Pharma drug development as well as her leadership roles in complex highly regulated health environments in Europe and the US make her ideally qualified to lead Creso Pharma through this critical initial period of multiple product developments and rapid growth.